The US Centers for Medicare and Medicaid services is taking a decidedly hands-off approach to 340B drug discount pricing and the new Medicare drug price negotiation authority.
Key Takeaways
- CMS does not appear interested in an active role ensuring 340B discount prices are appropriate for drugs subject to Medicare price negotiations.
The 2022 Inflation Reduction Act, which created the negotiation program, stipulates that 340B entities are eligible for either the new negotiated price or the 340B price, whichever is lower. But...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?